Loading market dashboard
Vivani Medical, Inc.
VANIHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Initiation of SLIM-1™ clinical trial, a Phase 1 study of NPM-139, a semaglutide implant under development for chronic weight management, on track for mid-year 2026 $28 million in cash, cash equivalents, restricted cash and capital commitments expected to fund current operating plan through the first half of 2027 ALAMEDA, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting subdermal drug implants utilizing its proprietary NanoPortal™ technology, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
Vivani Medical, Inc. (NASDAQ: VANI - Get Free Report) Director Gregg Williams purchased 1,587,301 shares of the firm's stock in a transaction that occurred on Wednesday, April 15th. The stock was purchased at an average price of $1.26 per share, for a total transaction of $1,999,999.26. Following the acquisition, the director owned 32,944,484 shares of the
Vivani Medical, Inc. (NASDAQ: VANI - Get Free Report) was the recipient of a significant increase in short interest in the month of March. As of March 31st, there was short interest totaling 532,131 shares, an increase of 65.0% from the March 15th total of 322,575 shares. Currently, 1.2% of the shares of the company are
Vivani Medical (NASDAQ: VANI - Get Free Report) and Verrica Pharmaceuticals (NASDAQ: VRCA - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations. Profitability This table compares Vivani Medical and
Vivani Medical (VANI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Successful completion of first-in-human study LIBERATE-1 paired with preclinical proof of concept data for a semaglutide implant advance NPM-139, miniature, ultra long-acting semaglutide implant under development for chronic weight management toward a Phase 1 clinical study with results anticipated by the end of 2026.
Vivani Medical (NASDAQ: VANI - Get Free Report) is projected to post its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect Vivani Medical to post earnings of ($0.10) per share for the quarter. Parties can check the company's upcoming Q4 2025 earning summary page for the latest details on the call
Vivani Medical, Inc. (NASDAQ: VANI - Get Free Report) was the recipient of a significant decrease in short interest in February. As of February 27th, there was short interest totaling 290,597 shares, a decrease of 25.4% from the February 12th total of 389,363 shares. Approximately 0.7% of the company's stock are sold short. Based on an
VYNE Therapeutics (NASDAQ: VYNE - Get Free Report) and Vivani Medical (NASDAQ: VANI - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk. Volatility and Risk VYNE Therapeutics has a
